California Public Employees Retirement System Cuts Stock Position in Elanco Animal Health Incorporated $ELAN

California Public Employees Retirement System cut its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 4.1% in the first quarter, HoldingsChannel.com reports. The firm owned 830,209 shares of the company’s stock after selling 35,888 shares during the period. California Public Employees Retirement System’s holdings in Elanco Animal Health were worth $19,867,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Elanco Animal Health during the 1st quarter valued at about $2,065,000. Goldman Sachs Group Inc. boosted its holdings in Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares in the last quarter. Empowered Funds LLC grew its stake in shares of Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after acquiring an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after acquiring an additional 76,408 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Elanco Animal Health by 2,006.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after acquiring an additional 295,651 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 4,971 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Rajeev A. Modi purchased 4,911 shares of the stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the acquisition, the insider owned 160,812 shares of the company’s stock, valued at $3,272,524.20. The trade was a 3.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ELAN shares. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. TD Cowen upped their target price on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. JPMorgan Chase & Co. upped their target price on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Morgan Stanley raised their target price on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $28.73.

Elanco Animal Health Stock Performance

ELAN opened at $25.41 on Thursday. Elanco Animal Health Incorporated has a 12-month low of $13.39 and a 12-month high of $27.72. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $12.69 billion, a PE ratio of -50.81, a P/E/G ratio of 1.67 and a beta of 1.68. The firm has a 50 day moving average of $23.85 and a two-hundred day moving average of $23.95.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06. The business had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.